SERELAXIN
Total Payments
$2.3M
Transactions
198
Doctors
22
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $5,500 | 1 | 0 |
| 2018 | $54,380 | 15 | 0 |
| 2017 | $2.2M | 182 | 22 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $2.2M | 133 | 96.5% |
| Consulting Fee | $56,592 | 14 | 2.5% |
| Travel and Lodging | $19,183 | 21 | 0.9% |
| Food and Beverage | $2,125 | 30 | 0.1% |
Payments by Type
Research
$2.2M
133 transactions
General
$77,900
65 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A MULTICENTER RANDOMIZED DOUBLE BLIND PLACEBOCONTROLLED PHASE III STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF SERELAXIN WHEN ADDED TO STANDARD THERAPY IN ACUTE HEART FAILURE PATIENTS | Novartis Pharmaceuticals Corporation | $1.5M | 0 |
| GENERAL PROGRAM SUPPORT FOR RLX030 | Novartis Pharmaceuticals Corporation | $378,542 | 0 |
| DECIPHERING THE CARDIORENAL EFFECTS OF SERELAXIN IN ACUTE HEART FAILURE A CANINE MODEL | Novartis Pharmaceuticals Corporation | $126,015 | 0 |
| A MULTICENTER OPEN LABEL DOSE ESCALATION STUDY TO EVALUATE SAFETY TOLERABILITY AND PHARMACOKINETICS OF RLX030 IN ADDITION TO STANDARD OF CARE THERAPY IN PEDIATRIC PATIENTS FROM BIRTH TO LESS THAN 18 YEARS OF AGE HOSPITALIZED WITH ACUTE HEART FAILURE AHF | Novartis Pharmaceuticals Corporation | $112,095 | 0 |
| A MULTICENTER OPEN LABEL DOSE ESCALATION STUDY TO EVALUATE SAFETY TOLERABILITY AND PHARMACOKINETICS OF RLX030 IN ADDITION TO STANDARD OF CARE THERAPY IN PEDIATRIC PATIENTS FROM BIRTH TO LESS THAN 18 YEARS OF AGE HOSPITALIZED WITH ACUTE HEART FAILURE AHF | NOVARTIS PHARMACEUTICALS CORPORATION | $19,850 | 0 |
| PROSPECTIVE DOUBLE BLIND MULTICENTER STUDY EVALUATING THE SAFETY OF REPEAT DOSES OF IV SERELAXIN IN SUBJECTS WITH CHRONIC HEART FAILURE | Novartis Pharmaceuticals Corporation | $11,272 | 0 |
| A MULTICENTER RANDOMIZED DOUBLE BLIND PLACEBOCONTROLLED PHASE III STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF SERELAXIN WHEN ADDED TO STANDARD THERAPY IN ACUTE HEART FAILURE PATIENTS | NOVARTIS PHARMACEUTICALS CORPORATION | $4,382 | 0 |
Top Doctors Receiving Payments for SERELAXIN
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Boston, MA | $2.2M | 134 |
| , M.D | Specialist | Washington, DC | $9,913 | 1 |
| , MD, MPH | Cardiovascular Disease | Stony Brook, NY | $8,135 | 2 |
| , MD | Emergency Medicine | Indianapolis, IN | $7,725 | 7 |
| , M.D | Cardiovascular Disease | Morristown, NJ | $7,390 | 6 |
| , MD | Specialist | New York, NY | $7,009 | 6 |
| , MD | Family Medicine | Orange, CA | $6,673 | 5 |
| , M.D, MPH | Internal Medicine | Boston, MA | $6,629 | 7 |
| , MD | Hypertension Specialist | Farmington, CT | $5,940 | 1 |
| Adam Devore | Internal Medicine | Durham, NC | $5,758 | 6 |
| , MD | Emergency Medicine | Cleveland, OH | $5,753 | 5 |
| , M.D | Internal Medicine | San Francisco, CA | $3,815 | 3 |
| , MD, MBA | Cardiovascular Disease | Cambridge, MA | $1,075 | 3 |
| , M.D | Cardiovascular Disease | Oklahoma City, OK | $422.00 | 1 |
| , M.D | Cardiovascular Disease | Lake Mary, FL | $184.00 | 1 |
| , MD | Internal Medicine | Pontiac, MI | $65.39 | 3 |
| , M.D | Emergency Medical Services | Detroit, MI | $36.21 | 1 |
| , M.D | Internal Medicine | Richmond, VA | $27.48 | 1 |
| , M.D | Cardiovascular Disease | Richmond, VA | $27.48 | 1 |
| , M.D | Thoracic Surgery (Cardiothoracic Vascular Surgery) | Richmond, VA | $24.66 | 1 |
| , MD | Advanced Heart Failure and Transplant Cardiology | Richmond, TX | $24.66 | 1 |
| , MD | Cardiovascular Disease | Sylmar, CA | $11.34 | 1 |
| , MD | Family Medicine | Indio, CA | $11.34 | 1 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $2.3M
- Total Doctors 22
- Transactions 198
About SERELAXIN
SERELAXIN is a drug associated with $2.3M in payments to 22 healthcare providers, recorded across 198 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2017 to 2019. In 2019, $5,500 was paid across 1 transactions to 0 doctors.
The most common payment nature for SERELAXIN is "Unspecified" ($2.2M, 96.5% of total).
SERELAXIN is associated with 7 research studies, including "A MULTICENTER RANDOMIZED DOUBLE BLIND PLACEBOCONTROLLED PHASE III STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF SERELAXIN WHEN ADDED TO STANDARD THERAPY IN ACUTE HEART FAILURE PATIENTS" ($1.5M).